284 related articles for article (PubMed ID: 20861820)
1. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
2. Interventions for metabolic bone disease in children with chronic kidney disease.
Hahn D; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
[TBL] [Abstract][Full Text] [Related]
3. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
[TBL] [Abstract][Full Text] [Related]
4. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA
Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
6. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
7. Are new vitamin D analogues in renal bone disease superior to calcitriol?
Salusky IB
Pediatr Nephrol; 2005 Mar; 20(3):393-8. PubMed ID: 15690188
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Effects of treatment of renal osteodystrophy on bone histology.
Malluche HH; Mawad H; Monier-Faugere MC
Clin J Am Soc Nephrol; 2008 Nov; 3 Suppl 3(Suppl 3):S157-63. PubMed ID: 18988701
[TBL] [Abstract][Full Text] [Related]
10. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
Thadhani RI; Rosen S; Ofsthun NJ; Usvyat LA; Dalrymple LS; Maddux FW; Hymes JL
Clin J Am Soc Nephrol; 2020 Mar; 15(3):384-391. PubMed ID: 32111702
[TBL] [Abstract][Full Text] [Related]
11. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.
Kalantar-Zadeh K; Shah A; Duong U; Hechter RC; Dukkipati R; Kovesdy CP
Kidney Int Suppl; 2010 Aug; (117):S10-21. PubMed ID: 20671739
[TBL] [Abstract][Full Text] [Related]
12. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.
Coburn JW; Maung HM; Elangovan L; Germain MJ; Lindberg JS; Sprague SM; Williams ME; Bishop CW
Am J Kidney Dis; 2004 May; 43(5):877-90. PubMed ID: 15112179
[TBL] [Abstract][Full Text] [Related]
13. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
[TBL] [Abstract][Full Text] [Related]
14. [Sevelamer hydrochloride and K/DOQI guidelines].
Yumita S
Clin Calcium; 2005 Sep; 15 Suppl 1():180-4. PubMed ID: 16279022
[No Abstract] [Full Text] [Related]
15. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
16. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
Llach F; Yudd M
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
[TBL] [Abstract][Full Text] [Related]
17. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
[TBL] [Abstract][Full Text] [Related]
18. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.
Covic A; Passlick-Deetjen J; Kroczak M; Büschges-Seraphin B; Ghenu A; Ponce P; Marzell B; de Francisco AL
Nephrol Dial Transplant; 2013 Sep; 28(9):2383-92. PubMed ID: 23787550
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
Ogata H; Koiwa F; Shishido K; Kinugasa E
Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
[TBL] [Abstract][Full Text] [Related]
20. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
